One of the primary goals of AdvantiGen is to develop monobodies and tandem monobodies for reagent, diagnostic and therapeutic use.  Furthermore by combining these monobodies with our patented infrared fluorophore technology AdvantiGen is able produce low-background infrared fluorescent monobodies, which can be utilized for novel cell and whole animal imaging research, as well as implemented as diagnostics for cancers and infectious diseases.